Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 USD | -1.64% | -9.77% | -89.21% |
05-16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
05-14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Sales 2022 | - | Sales 2023 | 2.2 3 | Capitalization | 13.61M 18.55M |
---|---|---|---|---|---|
Net income 2022 | -73M -99.47M | Net income 2023 | -37M -50.42M | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M 6.25M | Net Debt 2023 | 11.23M 15.3M | EV / Sales 2023 | 11,278,476 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | 10 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.69% |
Latest transcript on Seelos Therapeutics, Inc.
1 day | -1.64% | ||
1 week | -9.77% | ||
1 month | -46.24% | ||
3 months | -88.37% | ||
6 months | -88.10% | ||
Current year | -89.21% |
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 86-12-31 |
Director of Finance/CFO | 52 | 18-12-31 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 21-08-31 | |
Richard Pascoe
CHM | Chairman | 60 | 13-02-28 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 18-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.2 | -1.64% | 47,663 |
24-05-30 | 1.22 | -8.27% | 176,559 |
24-05-29 | 1.33 | -4.32% | 81,199 |
24-05-28 | 1.39 | +4.51% | 82,468 |
24-05-24 | 1.33 | -2.92% | 100,320 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-89.21% | 3.13M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SEEL Stock